Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria
Open Access
- 19 August 2013
- journal article
- research article
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 11 (10), 971-978
- https://doi.org/10.1111/ddg.12194
Abstract
At the end of 2012, more than 300 participants discussed and agreed on the update of the international guidelines on urticaria at the 4th International Consensus Meeting (URTICARIA 2012). Currently, the recommendations are in the final process of international coordination. In preparation for the update, questions were prepared by an expert panel; this was followed by a systematic literature search. The questions and the resulting recommendations were discussed by the participants and decided upon in an open vote. Consensus was defined as at least 75% agreement. The updated guidelines will modify and improve the currently available guidelines in various areas, especially in therapy. For the treatment of chronic urticaria, the new algorithm recommends a three‐step process starting with a standard dose of a non‐sedating H1 antihistamine. If there is an insufficient treatment response, the dosage should be increased up to four times. In, therapy refractory patients, omalizumab, cyclosporine A, or montelukast are advised in the third step. Short‐term corticosteroid treatment for a maximum of 10 days may be considered. H2 antihistamines and dapsone, which were included in the previous version of the guidelines, are absent in the updated and revised version because of changes in the evidence level.Keywords
Funding Information
- Genentech, GSK, Faes Moxie, Novartis, MSD, UCB und Uriach
- Bayer Schering, FAES, Merck, Novartis and Sanofi-Aventis
This publication has 20 references indexed in Scilit:
- Development, validation, and initial results of the Angioedema Activity ScoreAllergy, 2013
- Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapyJournal of Allergy and Clinical Immunology, 2013
- Practical algorithm for diagnosing patients with recurrent wheals or angioedemaAllergy, 2013
- Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous UrticariaNew England Journal of Medicine, 2013
- Development and construct validation of the angioedema quality of life questionnaireAllergy, 2012
- EAACI/GA²LEN/EDF/WAO guideline: management of urticariaAllergy, 2009
- EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticariaAllergy, 2009
- The German version of the chronic urticaria quality‐of‐life questionnaire: factor analysis, validation, and initial clinical findingsAllergy, 2009
- How to assess disease activity in patients with chronic urticaria?Allergy, 2008
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008